KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's disease.

Maria Cappello, Ciro Celsa

Med 6(2) 100572

PMID39954670
PMCID-
DOI10.1016/j.medj.2024.100572
发表日期2025-02-15
摘要

摘要

The VIVID-1 study is a phase 3 randomized controlled trial assessing the efficacy and safety of mirikizumab in moderate-to-severe active Crohn's disease.1 The study confirms the advantage of selective IL-23 inhibition, while the treat-through design and the choice of composite coprimary endpoints represent an innovative strategy in conducting clinical trials in Crohn's disease.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。